Advertisement

Topics

Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis

2017-08-02 13:53:21 | BioPortfolio

Summary

Study Design:

Double-blind randomized placebo-controlled clinical trial

Study Duration:

2 years

Study Center:

Single center Hospital de la Santa Creu i Sant Pau, Barcelona

Objectives:

To assess the effect of Vivomixx® on neuroinflammation and systemic inflammatory response in patients with cirrhosis

Description

Study variables Main variables

- Neuroinflammation

- Systemic inflammatory response Secondary variables

- Cognitive function

- Bacterial translocation

- Intestinal barrier

- Systemic oxidative damage

- Time until SBP or other bacterial infection resolution in patients with infections

- Incidence of complications of cirrhosis and mortality during the study 40 patients, 20 and 30 in each of the two substudies, respectively Diagnosis and Main Inclusion Criteria

- Decompensated patients with cirrhosis:

1. Outpatients with refractory ascites (substudy 1) (n=20)

2. Patients hospitalized because bacterial infection (substudy 2) (n=30)

Study Product:

Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)

Duration of administration:

30 days Follow up The following patients' assessments will be performed: in substudy 1 at baseline and at the end of the treatment (30 days), and in substudy 2 at baseline, on day 1, day 2, day 3, day 7, at infection resolution, and at discharge or day 30.

Clinical and analytical assessments will be performed every three months after the end of the study Comparator Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in addition to the standard of care) Statistical Methodology Fisher's exact test for categorical variables and Student's "t" test and Mann-Whitney and Wilcoxon tests for quantitative variables. Correlations will be assessed by Spearman test. A two-sided p value <0.05 will be considered statistically significant

Study Design

Conditions

Cirrhosis, Liver

Intervention

Vivomixx

Location

Hospital de la Santa Creu i Sant Pau
Barcelona
Spain
08025

Status

Recruiting

Source

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Results (where available)

View Results

Links

Published on BioPortfolio: 2017-08-02T13:53:21-0400

Clinical Trials [1880 Associated Clinical Trials listed on BioPortfolio]

Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)

Study Design: Double-blind placebo-controlled clinical trial Study Duration:2 years Study Center: Hospital de la Santa Creu i Sant Pau, Barcelona (single center) Objectives: To as...

Intestinal Barrier Function and Liver Cirrhosis

Patients with liver cirrhosis have an increased risk to develop life-threatening complications such as spontaneous bacterial peritonitis (SBP). Impairment in the intestinal barrier, change...

Can Probiotic Vivomixx Eradicate Colonization With ESBL?

Can probiotic Vivomixx eradicate Extended Spectrum BetaLactam (ESBL) colonization in adult patients?

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in...

Cirrhosis, Effects of TRAnsplantation and Diabetes

This observational study is aimed at assessing insulin secretion and sensitivity by the use of a mathematical modeling from oral glucose tolerance test in subjects with liver cirrhosis un...

PubMed Articles [4415 Associated PubMed Articles listed on BioPortfolio]

The Range and Reproducibility of the Liver Frailty Index.

The Liver Frailty Index (LFI), composed of three performance-based tests (grip strength, chair stands, balance), is a tool specifically developed in patients with cirrhosis to objectively measure phys...

Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.

Liver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, ...

Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis.

An association between diabetes mellitus (DM) and liver cirrhosis is well known but estimates of the prevalence of DM in patients with liver cirrhosis vary widely. A systematic review was undertaken t...

How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.

The definition of acute liver failure (ALF) usually implies no previous liver injury. Though, some patients admitted to liver transplantation centers with the diagnosis of ALF are obese or have diabet...

Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.

Noninvasive methods have been established to detect clinically significant portal hypertension in liver cirrhosis with variable limitations. The von Willebrand factor (vEF) has been found to increase ...

Medical and Biotech [MESH] Definitions

Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.

Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.

Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.

Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of Mallory hyaline bodies. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.

More From BioPortfolio on "Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Searches Linking to this Trial